Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Angelica M. Gutierrez Barrera"'
Autor:
Toma S. Omofoye, Huong T. Le-Petross, Niloofar Karbasian, Constance Albarracin, Angelica M. Gutierrez-Barrera, Sahand Sohrabi, Banu Arun, Kenneth R. Hess, Gary J. Whitman
Publikováno v:
Curr Probl Diagn Radiol
Objective: The purpose of this study is to review the mammographic and the ultrasound features of triple negative breast cancer (TNBC) patients and to investigate the potential effect of BRCA mutations on the imaging features of these patients. Metho
Autor:
Kimberly I. Muse, Banu Arun, Karen H. Lu, Trisha S Emborgo, Angelica M. Gutierrez Barrera, Jennifer K. Litton, Donika Saporito
Publikováno v:
JNCI Cancer Spectrum
Background Limited published literature exists on women with triple-negative breast cancer (TNBC) diagnosed over the age of 60 years with breast cancer gene (BRCA) pathogenic variants. Our study determined whether the rate of BRCA pathogenic variants
Autor:
Katherine Clifton, Gabriel N. Hortobagyi, Jennifer K. Litton, Henry Mark Kuerer, Constance Albarracin, Stacy L. Moulder, Banu Arun, Angelica M. Gutierrez-Barrera, Junsheng Ma, Roland L. Bassett
Publikováno v:
Breast Cancer Research and Treatment. 170:101-109
PURPOSE: As triple-negative breast cancers are associated with earlier recurrences and poorer survival, optimal treatment of early-stage breast cancer is essential. Several retrospective studies in triple-negative breast cancer have reported conflict
Autor:
Gaiane M. Rauch, Naoto T. Ueno, Jennifer K. Litton, Roland L. Bassett, Angelica M. Gutierrez Barrera, Stacy L. Moulder, Li Zhao, Debu Tripathy, Rosalind P. Candelaria, Vicente Valero, Banu Arun, Jason B White, Alastair M. Thompson, Rachel M. Layman, Elizabeth Ravenberg, Jianhua Zhang
Publikováno v:
Journal of Clinical Oncology. 38:1546-1546
1546 Background: Previous studies have related germline BRCA mutations to pathologic complete response (pCR) in TNBC cohorts. However, prospective data is lacking on the frequency of non- BRCA germline mutations and pCR in TNBC patients who received
Autor:
Gn. Hortobagyi, Jennifer K. Litton, Constance Albarracin, Ugur Akar, Angelica M. Gutierrez-Barrera, A. M. Gonzalez-Angulo, Banu Arun
Publikováno v:
Cancer Research. 70:P6-10
Background: Triple-negative breast cancer (TNBC) affects 10-17% of all breast cancers and is associated with a poor prognosis. The biology of TNBC is poorly understood; however, it has been shown that up to 60% of BRCA1 mutation carriers develop TNBC
Autor:
Jennifer K. Litton, Junsheng Ma, Angelica M. Gutierrez Barrera, Banu Arun, Roland L. Bassett, Katherine Clifton
Publikováno v:
Journal of Clinical Oncology. 35:576-576
576 Background: NSABP Protocol B-18 was a randomized trial which found no statistically significant difference in overall survival (OS) in patients (pts) receiving neoadjuvant (NAC) or adjuvant chemotherapy (AC), however outcome was not analyzed by b
Autor:
Angelica M. Gutierrez-Barrera, Diane Liu, Ugur Akar, Gabriel N. Hortobagyi, Ana M. Gonzalez-Angulo, Tunc Tasbas, E. Lin, Funda Meric-Bernstam, Banu Arun, Constance Albarracin, Soley Bayraktar, Jennifer K. Litton
More than 75% of breast cancers that develop in BRCA1 mutation carriers are triple-negative breast cancers (TNBC). The aim of this study was to compare the recurrence-free survival (RFS) and overall survival (OS) in high-risk patients with TNBC with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c20c301e164a0e8eb90ba278fb343bd
https://europepmc.org/articles/PMC4334122/
https://europepmc.org/articles/PMC4334122/
Publikováno v:
Cancer Research. 74:3218-3218
Triple negative breast cancer (TNBC), a subpopulation of breast cancer that has a high mortality rate, recently has been shown to be quite diverse with approximately 7 different molecular subtypes. As a result, treatment with an agent that can potent